Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
$2.63
$10.35M1.58352,864 shs120,938 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$2.68
-13.8%
$1.33
$0.89
$24.00
$13.61M2.161.60 million shs2.07 million shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$0.06
-1.0%
$0.11
$0.03
$10.79
N/A1.4247.79 million shs587.06 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$5.27
-1.3%
$4.71
$2.10
$6.07
$835.09M0.662.06 million shs2.22 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%+5.59%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
+16.92%+150.81%+141.09%+132.09%-85.62%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
+8.45%+6.73%-20.87%-91.68%-97.96%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
+11.95%+12.90%+19.20%+35.19%+147.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.2172 of 5 stars
0.05.00.00.03.00.00.6
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.5297 of 5 stars
3.32.00.00.01.12.51.3
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.1101 of 5 stars
2.41.00.04.20.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00
N/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0041,776.05% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2518.60% Upside

Current Analyst Ratings Breakdown

Latest XERS, NCNA, AGRX, ADMS, and MBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.98M0.52N/AN/A($5.51) per share-0.27
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A($2.11) per shareN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$1.34 per shareN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M4.06N/AN/A($0.20) per share-26.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$3.65N/AN/A-36.24%N/A-147.37%N/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.000.00N/AN/AN/AN/A-80.79%8/12/2025 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$7.020.00N/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.300.00N/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)

Latest XERS, NCNA, AGRX, ADMS, and MBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.56
0.38
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.34
1.34
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.25
1.25
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.72
1.17

Institutional Ownership

CompanyInstitutional Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
69.97%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
18.90%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
6.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
306.86 million6.82 millionNot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million4.37 millionNot Optionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
306.08 million4.18 millionNot Optionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.38 million146.27 millionOptionable

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance
Xeris Announces Details for Analyst & Investor Day

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamas Pharmaceuticals stock logo

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Agile Therapeutics stock logo

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$2.68 -0.43 (-13.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.66 -0.03 (-0.93%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.06 0.00 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.06 0.00 (-2.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$5.27 -0.07 (-1.31%)
Closing price 04:00 PM Eastern
Extended Trading
$5.27 0.00 (0.00%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.